News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Graham Collins: TRANSFORM Study – Liso-Cel vs Standard 2nd Line in 1st Relapse Large B-Cell NHL
Graham Collins/X
Jul 9, 2025, 16:58

Graham Collins: TRANSFORM Study – Liso-Cel vs Standard 2nd Line in 1st Relapse Large B-Cell NHL

Graham Collins, Associate Professor, Haematology and Lymphoma Specialist at Oxford Cancer and Haematology Centre, shared a post on X:

“Kamdar et al; 3y FU of TRANSFORM study – Liso-cel vs standard 2nd line in 1st relapse large B-cell NHL.

Impressive PFS & EFS benefit Trend to OS but not stat significant. 66% crossed over to liso-cel from control arm.

No new tox signal.”

Title: Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study

Authors: Manali Kamdar, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Victor A. Chow, Sandrine Montheard, Josu Santamaria, Silvia Colicino, Ken Ogasawara, Lara Stepan, Fei Fei Liu, Jeremy S. Abramson

Read Full Article.

Transform study

More posts featuring Graham Collins on OncoDaily.

B-cell NHL Bertram Glass cancer Fei-Fei Liu Francisco Hernandez-Ilizaliturri Franck Morschhauser Graham Collins Jeremy S. Abramson Jon Arnason Josu Santamaria Kamdar Ken Ogasawara Koji Izutsu Lara Stepan large B-cell NHL Manali Kamdar Matthew Lunning OncoDaily Oncology Patrick B. Johnston Pim Mutsaers Sami Ibrahimi Sandrine Montheard Scott R. Solomon Silvia Colicino Stephan Mielke TRANSFORM study Veronika Bachanova Victor A. Chow
Special Coverage
Opinion
Jul 28, 2025, 03:49
Ian Davis: Two Opinions That Are Either Unpopular or Not Widely Held
Blog
Jul 28, 2025, 03:33
Fundación Aladinas's Commitment to the First Pediatric Palliative Care Hospitalization Unit in Spain
Blog
Jul 27, 2025, 18:45
Thanks for Showing Up, Sharing Your Work, and Believing in Collaboration at KCRS25 - KidneyCAN
Blog
Jul 27, 2025, 18:34
Hamza Hashmi: Sharing Ideas, Research, and Debates on Myeloma at the MM Sparks Event in Merida
Blog
Jul 27, 2025, 18:26
Cathy Eng: Always a Pleasure to Listen to Kristen Ciombor Give a Lecture about Immunotherapy in MSI-S CRC
Blog
Jul 27, 2025, 17:40
Aladina Foundation's Psychooncologists Offer a Consultation Outside the Hospital for Free
Opinion
Jul 27, 2025, 17:27
Ian Davis: Why Chemotherapy Has Not Stopped Working in Metastatic Prostate Cancer for More than 20 Years
Blog
Jul 27, 2025, 16:53
Luis E. Raez: The FLASCO “Breaking Barriers” Conference Returns This November
Career
Jul 27, 2025, 16:20
Justin Perry Has Been Promoted to Associate Member at Memorial Sloan Kettering Cancer Center
Blog
Jul 27, 2025, 16:04
Helena Linardou: ESMO Virtual Journal Club – July 2025 Edition
Blog
Jul 27, 2025, 15:57
A Deep Dive Into the Most Important Lung Cancer Trials Presented at ASCO25 - IASLC
Blog
Jul 27, 2025, 15:38
Sergio Cifuentes Canaval: First Meeting of Young Oncologists Group